Interim estimates of 2014/15 vaccine effectiveness against influenza A(H3N2) from Canada s Sentinel Physician Surveillance Network, January 2015.

Interim estimates of 2014/15 vaccine effectiveness against influenza A(H3N2) from Canada s Sentinel Physician Surveillance Network, January 2015. Euro Surveill. 2015;20(4) Authors: Skowronski D, Chambers C, Sabaiduc S, De Serres G, Dickinson J, Winter A, Drews S, Fonseca K, Charest H, Gubbay J, Petric M, Krajden M, Kwindt T, Martineau C, Eshaghi A, Bastien N, Li Y PMID: 25655053 [PubMed - in process]
Source: Euro Surveill - Category: Infectious Diseases Authors: Tags: Euro Surveill Source Type: research

Related Links:

Flu season is always unpredictable. Different viral strains circulate each year, which makes forecasting the disease’s spread—and formulating the annual flu vaccine—an educated guessing game. Even so, the 2019-2020 flu season has been particularly unusual. Influenza B, the viral strain that usually circulates toward the end of flu season, instead emerged first this year, shifting usual transmission patterns. A vaccine mismatch and reduced immunity to influenza B may have contributed to the early and severe start of this flu season. What does that mean for the months ahead? TIME asked Lynnette Brammer, an ...
Source: TIME: Health - Category: Consumer Health News Authors: Tags: Uncategorized Infectious Disease Source Type: news
(CNN) — This year’s flu vaccine is “not a very good match” for a common strain of the flu that’s especially tough on children, according to the nation’s top infectious disease doctor. “It’s not a very good match for B/Victoria,” said Dr. Anthony Fauci, director of the National Institute of Allergy and Infectious Diseases, referring to the strain. “It’s not an awful match, but it’s not a very good match.” Children are particularly susceptible to influenza B/Victoria. Fauci said even though the match for B/Victoria isn’t great, a flu shot can...
Source: WBZ-TV - Breaking News, Weather and Sports for Boston, Worcester and New Hampshire - Category: Consumer Health News Authors: Tags: Health News Syndicated CBSN Boston CNN Flu Vaccine Source Type: news
CONCLUSIONS: The immunogenicity of QIV for common ingredients was similar to that of TIV, but the former exhibited significantly higher immunogenicity for the unique lineage. QIV also had the same reliable safety as TIV. PMID: 31948819 [PubMed - as supplied by publisher]
Source: Vaccine - Category: Allergy & Immunology Authors: Tags: Vaccine Source Type: research
Abstract Canada's national influenza season started in week 47 between November 17 to 23, 2019. Of the 3,762 laboratory-confirmed influenza detections reported from August 25 to December 14, 2019, 61% were influenza A, and of those subtyped, 68% were A(H3N2). Influenza B detections are above average for this time of year. Indicators of influenza activity are within the expected range for this time of year. The majority of hospitalizations reported by provinces and territories have been associated with influenza A(H3N2) (76%), and the greatest proportion have been among adults 65 years and older (40%). Among sentin...
Source: Can Commun Dis Rep - Category: Infectious Diseases Authors: Tags: Can Commun Dis Rep Source Type: research
Publication date: 24 December 2019Source: Cell Reports, Volume 29, Issue 13Author(s): Seth J. Zost, Juhye Lee, Megan E. Gumina, Kaela Parkhouse, Carole Henry, Nicholas C. Wu, Chang-Chun D. Lee, Ian A. Wilson, Patrick C. Wilson, Jesse D. Bloom, Scott E. HensleySummaryAntibodies targeting the receptor binding site (RBS) of the influenza virus hemagglutinin (HA) protein are usually not broadly reactive because their footprints are typically large and extend to nearby variable HA residues. Here, we identify several human H3N2 HA RBS-targeting monoclonal antibodies (mAbs) that are sensitive to substitutions in conventional anti...
Source: Cell Reports - Category: Cytology Source Type: research
CONCLUSION: The investigational QIV was immunogenic with an acceptable safety profile in children 6 months to 8 years of age. CLINICAL TRIAL REGISTRATION: NCT03336593. PMID: 31862195 [PubMed - as supplied by publisher]
Source: Vaccine - Category: Allergy & Immunology Authors: Tags: Vaccine Source Type: research
Authors: Hallmann-Szelińska E, Łuniewska K, Szymański K, Kowalczyk D, Sałamatin R, Masny A, Brydak LB Abstract The World Health Organization estimates that influenza virus infects 3-5 million people worldwide every year, of whom 290,000 to 650,000 die. In the 2016/2017 epidemic season in Poland, the incidence of influenza was 1,692 per 100,000 population. The influenza A virus, subtype A/H3N2/, was the predominant one in that season. However, in the most recent 2017/2018 epidemic season, the incidence exceeded 1,782 per 100,000 already by August of 2018. In this season, influenza B virus predominated, while the...
Source: Advances in Experimental Medicine and Biology - Category: Research Tags: Adv Exp Med Biol Source Type: research
Conclusion This study is the first to report on the VE against all types of influenza in all age groups using an RIDT. The VE varied with both age and influenza subtype. PMID: 31787695 [PubMed - as supplied by publisher]
Source: Internal Medicine - Category: Internal Medicine Tags: Intern Med Source Type: research
CONCLUSION: Persistence of antibodies at 6 months was more favorable against the influenza A strains than against the B strains. Persistence of antibodies to additional B strain at 6 months was superior in the quadrivalent vaccine group. The immunity of primed children with different B strains was not superior to that of the unprimed group with another B strain. PMID: 31779056 [PubMed - in process]
Source: Journal of Korean Medical Science - Category: Biomedical Science Tags: J Korean Med Sci Source Type: research
In this study, we generated VLPs vaccine containing hemagglutinin (HA) and matrix protein (M1) of the 2009 pandemic H1N1, and investigated the protective efficacies induced by VLPs vaccine and commercial monovalent H1N1 pandemic split vaccine from Sanofi-Pasteur. Mice were intramuscularly immunized with either VLPs vaccine or split vaccine and subsequently challenge-infected with homologous virus (A/California/04/2009, H1N1) or heterosubtypic virus (A/Philippines/82, H3N2) after 4.5 months. VLPs vaccination demonstrated a higher level of protective efficacy against homologous viruses compared to split vaccine, as lessened ...
Source: Immunological Investigations - Category: Allergy & Immunology Tags: Immunol Invest Source Type: research
More News: H3N2 | Infectious Diseases | Influenza | Influenza Vaccine | Vaccines